Compare IOT & BIIB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IOT | BIIB |
|---|---|---|
| Founded | 2015 | 1978 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Retail: Computer Software & Peripheral Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 22.8B | 24.2B |
| IPO Year | 2021 | 1991 |
| Metric | IOT | BIIB |
|---|---|---|
| Price | $41.41 | $174.28 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 11 | 22 |
| Target Price | $50.36 | ★ $177.40 |
| AVG Volume (30 Days) | ★ 5.8M | 2.0M |
| Earning Date | 12-04-2025 | 10-30-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 10.97 |
| Revenue | $1,520,629,000.00 | ★ $10,065,900,000.00 |
| Revenue This Year | $27.68 | $3.61 |
| Revenue Next Year | $20.63 | N/A |
| P/E Ratio | ★ N/A | $15.86 |
| Revenue Growth | ★ 28.96 | 4.77 |
| 52 Week Low | $31.40 | $110.04 |
| 52 Week High | $61.90 | $185.17 |
| Indicator | IOT | BIIB |
|---|---|---|
| Relative Strength Index (RSI) | 53.28 | 55.41 |
| Support Level | $36.88 | $169.24 |
| Resistance Level | $45.50 | $180.79 |
| Average True Range (ATR) | 1.95 | 5.36 |
| MACD | 0.52 | -1.56 |
| Stochastic Oscillator | 45.43 | 33.70 |
Samsara Inc provides an end-to-end solution for operations. The company's Connected Operations Platform consolidates data from its IoT devices and a growing ecosystem of connected assets and third-party systems, and makes it easy for organizations to access, analyze, and act on data insights using its cloud dashboard, custom alerts and reports, mobile apps, and workflows.. The company derives almost all of its revenue from subscription services. Geographically, it derives a majority of its revenue from the United States. The company's customers ranges from small and medium-sized businesses to state and local governments.
Biogen is an established biopharmaceutical company focused on treatments for neurological diseases and rare diseases. Its declining multiple sclerosis franchise is its largest revenue generator and contributed 45% of total revenue in 2024. Biogen also generates significant revenue from its CD20 collaboration agreements with Roche (18% of total in 2024), which includes oncology drugs Rituxan and Gazyva and multiple sclerosis drug Ocrevus. Biogen's newer franchises include Spinraza (spinal muscular atrophy, with partner Ionis), Leqembi (Alzheimer's disease, collabroation revenue from its partner Eisai), Skyclarys (Friedreich's ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (amyotrophic lateral sclerosis, Ionis).